Stem Cell Clinic

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell…

By Induced Pluripotent Stem Cells

DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Under the agreement, Aprea will supply its proprietary WEE1 kinase inhibitor, APR-1051, to support preclinical research aimed at exploring its potential in treating HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) expressing genomic markers of replication stress.

Read more:
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell...

Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th

By Induced Pluripotent Stem Cells

NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the iAccess Alpha Virtual Best Ideas Spring Conference 2025 on March 25 and 26, 2025.

Go here to see the original:
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s…

By Induced Pluripotent Stem Cells

MIAMI, March 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the publication in Nature Medicine of results from the CLEAR MIND Phase 2a clinical trial evaluating laromestrocel (Lomecel-B™) as a potential cellular therapy for mild Alzheimer’s disease (AD). The article is also available online here. The International Nonproprietary Names (INN) Expert Committee of the World Health Organization recently approved “laromestrocel” for the non-proprietary name of Lomecel-B™.

More here:
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s...

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being…

By Induced Pluripotent Stem Cells

LONDON, March 11, 2025 (GLOBE NEWSWIRE) -- Kaerus Bioscience (www.kaerusbio.com), a clinical-stage biopharmaceutical company created by Medicxi for the development of therapeutics for rare genetic syndromes of neurodevelopment, today announces the successful completion of its Phase 1 clinical trial of KER-0193, a novel BK channel modulator the company is developing for Fragile X syndrome (FXS) and other neurodevelopmental conditions.

Go here to see the original:
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being...

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its…

By Induced Pluripotent Stem Cells

• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities.

Read the original:
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its...

GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

By Induced Pluripotent Stem Cells

LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it received notice on March 10, 2025 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2), also known as the “minimum bid price rule.”

Visit link:
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

By Induced Pluripotent Stem Cells

ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the quarter and full year ended December 31, 2024, and provided an overview of the Company’s progress.

Read the original post:
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

By Global News Feed

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics, today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HErEF).

Read more from the original source:
Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

→←